Abstract
Protein-protein and protein-nucleic acid interactions are involved in many regulatory cellular pathways, playing a key role in cell growth and proliferation, as well as in the progression and development of various diseases such as infectious diseases. Especially in the anti-AIDS research, protein-protein and protein-nucleic acid complexes are being considered as promising targets for pharmaceutical interventions aimed at overcoming the drug resistance observed for most of the classic enzyme inhibitors. Consequently, more and more protein-protein and protein-nucleic acid interaction inhibitors have being identified and developed as candidate agents for antiretroviral therapy. Here, we review the state of the art in the discovery and development of protein-protein and protein-nucleic acid interaction inhibitors that block the main steps of the HIV-1 replication cycle, giving a medicinal chemistry-oriented view of strategies for inhibiting these regulatory interactions that are involved in the entry process, in the dimerization of reverse transcriptase and protease enzymes, and in the activity of the nucleocapsid protein by means of small molecular potential therapeutic agents.
Keywords: AIDS, entry, gp120-CD4, HIV-1, nucleocapsid protein NCp7, reverse transcriptase dimerization, protein-nucleic acid interactions, protein-protein interactions, protease, cytotoxicity
Current Pharmaceutical Design
Title: Targeting Protein-Protein and Protein-Nucleic Acid Interactions for Anti-HIV Therapy
Volume: 17 Issue: 33
Author(s): Mattia Mori, Fabrizio Manetti and Maurizio Botta
Affiliation:
Keywords: AIDS, entry, gp120-CD4, HIV-1, nucleocapsid protein NCp7, reverse transcriptase dimerization, protein-nucleic acid interactions, protein-protein interactions, protease, cytotoxicity
Abstract: Protein-protein and protein-nucleic acid interactions are involved in many regulatory cellular pathways, playing a key role in cell growth and proliferation, as well as in the progression and development of various diseases such as infectious diseases. Especially in the anti-AIDS research, protein-protein and protein-nucleic acid complexes are being considered as promising targets for pharmaceutical interventions aimed at overcoming the drug resistance observed for most of the classic enzyme inhibitors. Consequently, more and more protein-protein and protein-nucleic acid interaction inhibitors have being identified and developed as candidate agents for antiretroviral therapy. Here, we review the state of the art in the discovery and development of protein-protein and protein-nucleic acid interaction inhibitors that block the main steps of the HIV-1 replication cycle, giving a medicinal chemistry-oriented view of strategies for inhibiting these regulatory interactions that are involved in the entry process, in the dimerization of reverse transcriptase and protease enzymes, and in the activity of the nucleocapsid protein by means of small molecular potential therapeutic agents.
Export Options
About this article
Cite this article as:
Mori Mattia, Manetti Fabrizio and Botta Maurizio, Targeting Protein-Protein and Protein-Nucleic Acid Interactions for Anti-HIV Therapy, Current Pharmaceutical Design 2011; 17 (33) . https://dx.doi.org/10.2174/138161211798220972
DOI https://dx.doi.org/10.2174/138161211798220972 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Withania somnifera Phytochemicals Confer Neuroprotection by Inhibition of the Catalytic Domain of Human Matrix Metalloproteinase-9
Letters in Drug Design & Discovery P2Y Receptor Activation Affects the Proliferation and Differentiation of Glial and Neuronal Cells: A Focus on Rat C6 Glioma Cells
Current Neuropharmacology Biological Activities of Eco-Friendly Synthesized Hantzsch Adducts
Medicinal Chemistry Oncogenic MicroRNAs in the Genesis of Leukemia and Lymphoma
Current Pharmaceutical Design Inhibitor at the Gates, Inhibitor in the Chamber: Allosteric and Competitive Inhibitors of the Proteasome as Prospective Drugs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Current Status on Natural Products with Antitumor Activity from Brazilian Marine Sponges
Current Pharmaceutical Biotechnology Dendritic Cell Immunotherapy for Melanoma
Reviews on Recent Clinical Trials The Recent Medicinal Chemistry Development of Jak2 Tyrosine Kinase Small Molecule Inhibitors
Current Medicinal Chemistry Minocycline and Doxycycline: More Than Antibiotics
Current Molecular Pharmacology <sup>68</sup>Ga-labeled HBED-CC Variant of uPAR Targeting Peptide AE105 Compared with <sup>68</sup>Ga-NODAGA-AE105
Anti-Cancer Agents in Medicinal Chemistry Editorial: [Hot Topic: The Role of Nuclear Medicine in the Management of Patients with Glioblastoma Multiforme]
Current Radiopharmaceuticals Disease-Responsive Drug Delivery: The Next Generation of Smart Delivery Devices
Current Drug Metabolism Targeting Ion Channels for New Strategies in Cancer Diagnosis and Therapy
Current Clinical Pharmacology P2Y Receptors: Focus on Structural, Pharmacological and Functional Aspects in the Brain
Current Medicinal Chemistry Brain Tumor Detection from MR Images Employing Fuzzy Graph Cut Technique
Recent Advances in Computer Science and Communications Effect of PUFAs Oral Administration on the Amount of Apoptotic Caspases Enzymes in Gastric Cancer Patients Undergoing Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Design, Preparation and Characterization of Modular Squalene-based Nanosystems for Controlled Drug Release
Current Topics in Medicinal Chemistry Neuroprotection by Estrogen and Progesterone in Traumatic Brain Injury and Spinal Cord Injury
Current Neuropharmacology Nanotechnology-enabled Chemodynamic Therapy and Immunotherapy
Current Cancer Drug Targets Unsupervised End-to-End Brain Tumor Magnetic Resonance Image Registration Using RBCNN: Rigid Transformation, B-Spline Transformation and Convolutional Neural Network
Current Medical Imaging